ReviewUnited European gastroenterology journal2025
Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Novel Mechanisms and Prevention by Drugs.
Review in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of indomethacin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A comprehensive meta-analysis of randomized controlled trials.World journal of gastroenterology · 2026Pooled it
- Clinical Factors Associated with Prolonged Hospitalization in Patients Undergoing ERCP: A Tertiary-Care Cohort Study.Journal of clinical medicine · 2026Article
- Impact of body mass index on the outcomes of endoscopic retrograde cholangiopancreatography: a systematic review and network meta-analysis.Clinical endoscopy · 2026Article
- Safety and feasibility of omitting routine endoscopic nasobiliary drainage after ERCP for common bile duct stones: a prospective comparative study.BMC surgery · 2026Article
- Clinical efficacy of percutaneous transhepatic biliary drainage for obstructive jaundice in pancreatic cancer and risk factors for postoperative pancreatitis.American journal of translational research · 2026Article
- Harnessing early enzymatic biomarkers and cytokines for risk prediction in post-endoscopic retrograde cholangiopancreatography pancreatitis.World journal of gastroenterology · 2025Article
- Prevention, Detection, and Management of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.Gut and liver · 2025Review
- Update on the Pancreas: Disease Mechanisms and Therapeutic Strategies.United European gastroenterology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is becoming more common than first-line therapy for pancreaticobiliary duct disorders. However, post-ERCP pancreatitis is the most common complication of ERCPs, and affects about 10% of cases. In this review, we provide an overview of the mechanisms purported to cause post-ERCP pancreatitis as well as associated risk factors. We discuss measures that are in practice for post-ERCP pancreatitis pharmaco-prophylaxis, along with advances in the pipeline. We emphasize that there is still a pressing need to narrow the incidence of post-ERCP pancreatitis and that a mechanistic approach may reveal the greatest benefit from utilizing a combination of targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.